- Home
- BYSI vs TIL Comparison
BYSI vs TIL Comparison
Compare BYSI & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- TIL
- Stock Information
- Founded
- BYSI 2010
- TIL 2018
- Country
- BYSI United States
- TIL United States
- Employees
- BYSI N/A
- TIL N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- TIL Health Care
- Exchange
- BYSI Nasdaq
- TIL Nasdaq
- Market Cap
- BYSI 99.5M
- TIL 90.7M
- IPO Year
- BYSI 2017
- TIL 2021
- Fundamental
- Price
- BYSI $2.39
- TIL $39.46
- Analyst Decision
- BYSI
- TIL Buy
- Analyst Count
- BYSI 0
- TIL 3
- Target Price
- BYSI N/A
- TIL $103.67
- AVG Volume (30 Days)
- BYSI 24.9K
- TIL 179.7K
- Earning Date
- BYSI 01-01-0001
- TIL 11-11-2024
- Dividend Yield
- BYSI N/A
- TIL N/A
- EPS Growth
- BYSI N/A
- TIL N/A
- EPS
- BYSI N/A
- TIL N/A
- Revenue
- BYSI $1,876,000.00
- TIL N/A
- Revenue This Year
- BYSI N/A
- TIL N/A
- Revenue Next Year
- BYSI N/A
- TIL N/A
- P/E Ratio
- BYSI N/A
- TIL N/A
- Revenue Growth
- BYSI 21.03
- TIL N/A
- 52 Week Low
- BYSI $0.78
- TIL $6.08
- 52 Week High
- BYSI $4.00
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- BYSI 55.53
- TIL 44.61
- Support Level
- BYSI $2.27
- TIL $38.18
- Resistance Level
- BYSI $2.53
- TIL $45.07
- Average True Range (ATR)
- BYSI 0.19
- TIL 5.46
- MACD
- BYSI -0.00
- TIL -2.84
- Stochastic Oscillator
- BYSI 53.33
- TIL 17.79
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.